Vericel Corp Ord (VCEL) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Total Cash From Operating Activities Chart for Vericel Corp Ord
Vericel Corp Ord (VCEL) operating cash flow for FY2025 was USD 51.9M, a -10.8% change from FY2024. Vericel Corp Ord's operating cash flow moved from USD -9.1M in 1995 to USD 51.9M in 2025 over 30 years. Operating cash flow compound annual growth rate: 5-year CAGR of 24.2%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.18B
- Implied Share Price
- $42.53
- Enterprise Value
- $2.28B
- Revenue (TTM)
- $306.30M
- EBITDA
- $31.15M
- Profit Margin
- 7.91%
- Trailing P/E
- 90.49
- Forward P/E
- 97.09
- Price/Book (MRQ)
- 6.36
- Price/Sales (TTM)
- 7.11
- EV/EBITDA
- 59.10
- EV/Revenue
- 7.46
- Dividend Yield
- —
- Book Value
- $7.23
- Free Cash Flow (FY2025)
- $24.75M
- Free Cash Flow Yield
- 1.14%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.